[{"indications": "Indications\u00a0\n(From 5.3.5 Respiratory syncytial virus: British National Formulary)\n5.3.5 Respiratory syncytial virus", "name": "PALIVIZUMAB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.5 Respiratory syncytial virus", "PALIVIZUMAB"], "cautions": "Cautions\u00a0moderate to severe acute infection or febrile illness; thrombocytopenia; serum-palivizumab concentration\r\nmay be reduced after cardiac surgery; hypersensitivity\r\nto humanised monoclonal antibodies", "side-effects": "Side-effects\u00a0fever, injection-site reactions, nervousness; less commonly diarrhoea, vomiting, constipation, haemorrhage,\r\nrhinitis, cough, wheeze, pain, drowsiness, asthenia, hyperkinesia,\r\nleucopenia, and rash; also reported, apnoea, hypersensitivity reactions\r\n(including anaphylaxis), convulsions and thombocytopenia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/82142.htm", "doses": ["By intramuscular injection (preferably\r\nin anterolateral thigh), 15\u00a0mg/kg once a month during season of RSV\r\nrisk (child undergoing cardiac bypass surgery, 15\u00a0mg/kg as soon as\r\nstable after surgery, then once a month during season of risk); injection\r\nvolume over 1\u00a0mL should be divided between more than one site"]}]